- RELX Technology conducts extensive research to verify product safety via a series of thorough assessments
Dubai, UAE 27 October 2020: RELX Technology, Asia’s leading tech startup company, has started a program of systematic research centered on pre-clinical safety assessments. Located in Shenzhen’s International Bioindustry Valley in China, researchers at the new state-of-the-art bioscience laboratory are carrying out a comprehensive evaluation concerning e-cigarette products and their effects on user health.
“Like other regions around the world, e-cigarettes can be viewed with suspicion in the Middle East because as a whole, the industry has incomplete knowledge,” said Ziad Houdeib, RELX Technology’s UAE General Manager. “Our China-based bioscience lab is on a mission to explore answers to questions that aren’t yet known. By paying close attention to the science, our aim is to collect sound evidence and prove the potential for e-cigarettes to be less harmful.”
“Science is at the heart of everything we do, and we invest heavily in R&D. We rely on our findings to determine our direction, in alignment with our long-term mission which is to provide innovative and better smoking alternatives”, added Houdeib.
RELX Technology is currently involved in a variety of research projects in various relevant disciplines. In addition to universities and scientific centers in China, the company is also collaborating with nine scientific research institutions. Findings from these collaborations, together with those from the new bioscience laboratory, are sure to inform and educate adult smokers in the Middle East in the years ahead while ensuring they can access the best possible alternatives to combustible cigarettes.
Wen Yilong, Co-founder and Head of Supply Chains and Science, Research and Development, RELX Technology, said: “As we look ahead, our mission is to collect as much evidence as possible through a detailed scientific approach and prove beyond any doubt that e-cigarettes are less harmful. The work we are conducting at the bioscience lab is revolutionary for our industry and will reassure adult smokers across the Middle East and globally that they have a viable and better alternative to smoking conventional cigarettes.”
In addition to opening the new bioscience lab, RELX Technology previously established a chemical and physical lab in 2018 that is certified by the internationally-recognized China National Accreditation Service for Conformity Assessment (CNAS). The Shenzhen bioscience laboratory is set to further drive industry-wide testing and investigation, contributing to a greater scientific understanding for the industry.
RELX Technology invests heavily in R&D, testing, and product design to ensure that its products meet stringent standards and the more-demanding adult smoker consumer base. The brand’s flagship product, the RELX Infinity, received global recognition earlier this year, winning the sought-after product design Red Dot Award in 2020 in March.
ABOUT RELX Technology
Founded in January 2018, RELX Technology is one of Asia’s fastest growing tech startups that is rapidly expanding its footprint across the globe by developing cutting-edge tobacco harm-reduction products with a focus on technology and responsibility. The company’s ethos has attracted global talents with a passion for technology from Uber, Proctor and Gamble, Huawei, Beats, and L’Oréal. And with investment by multinational venture capitalists Source Code Capital, IDG Capital, and Sequoia Capital and with an eye on innovation, RELX Technology has filed over 400 patents – an average of one every two days – unprecedented for a two-year ‘young’ startup.